Will Ince, MRCP, FRCR, advises community oncologists to prepare for patients with recurrent or metastatic head and neck squamous cell carcinoma to live longer, which will increase clinic volume and affect service organization.
Back
Evolving First-Line Strategies in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
Kevin Harrington, MBBS, PhD, FRCP, FRCR; Will Ince, MRCP, FRCR; and Ross Merkin, MD, discuss first-line strategies for recurrent or metastatic head and neck squamous cell carcinoma, including how human papillomavirus status shapes tumor biology and testing, efficacy and safety data for emerging epidermal growth factor receptor-directed combinations, toxicity management, dosing and administration, and treatment sequencing.
Evolving First-Line Strategies in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
Episodes
All
All
Closing reflections on recurrent or metastatic head and neck squamous cell carcinoma center on human papillomavirus (HPV) status and curative-intent strategies.
Kevin Harrington, MBBS, PhD, FRCP, FRCR, opens a discussion on how checkpoint inhibitors changed first-line treatment for recurrent or metastatic head and neck squamous cell carcinoma.
Ross Merkin, MD, explains that the goal of first-line therapy for recurrent or metastatic head and neck squamous cell carcinoma is to help the patient, which usually means treating the cancer.
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Amivantamab and Hyaluronidase for Metastatic HNSCC
2
Routine Breast Imaging May Offer Little Benefit After Double Mastectomy for Early Breast Cancer
3
BCG Optimization Becomes a Priority as Durvalumab Gains a Role in High-Risk NMIBC
4
Dr Cai on the Rationale for Evaluating Rocbrutinib Plus R-CHOP in Non-GCB DLBCL and MCL
5